Journal
CELL
Volume 165, Issue 4, Pages 910-920Publisher
CELL PRESS
DOI: 10.1016/j.cell.2016.03.029
Keywords
-
Categories
Funding
- Sir Henry Wellcome Fellowship [098847/Z/12/Z]
- Cancer Research UK Career Establishment Award [C37293/A12905]
- Cancer Research UK Institute Award [A19258]
- NIH [U54-CA112967, R01-CA96504]
- Rosetrees Trust [M286]
- Cancer Research UK [12905, 19258, 15675] Funding Source: researchfish
- Rosetrees Trust [M286] Funding Source: researchfish
- Wellcome Trust [098847/Z/12/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Oncogenic mutations regulate signaling within both tumor cells and adjacent stromal cells. Here, we show that oncogenicKRAS(KRAS G12D) also regulates tumor cell signaling via stromal cells. By combining cell-specific proteome labeling with multivariate phosphoproteomics, we analyzed heterocellular KRAS G12D signaling in pancreatic ductal adenocarcinoma (PDA) cells. Tumor cell KRAS G12D engages heterotypic fibroblasts, which subsequently instigate reciprocal signaling in the tumor cells. Reciprocal signaling employs additional kinases and doubles the number of regulated signaling nodes from cell-autonomous KRAS G12D. Consequently, reciprocal KRAS G12D produces a tumor cell phosphoproteome and total proteome that is distinct from cell-autonomous KRAS G12D alone. Reciprocal signaling regulates tumor cell proliferation and apoptosis and increases mitochondrial capacity via an IGF1R/AXL-AKT axis. These results demonstrate that oncogene signaling should be viewed as a heterocellular process and that our existing cell-autonomous perspective underrepresents the extent of oncogene signaling in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available